http://orcid.org/0000-0001-5926-5407
About the Authors
- Xuan Wang
-
Roles Conceptualization, Investigation, Writing – original draft
* E-mail: xuan.wang@mcb.uu.se
Affiliation Science for Life Laboratory, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
- Andris Elksnis
-
Roles Conceptualization, Investigation, Writing – original draft
Affiliation Science for Life Laboratory, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
- Per Wikström
-
Roles Conceptualization, Investigation, Writing – original draft
Affiliation Glucox Biotech AB, Stockholm, Sweden
- Erik Walum
-
Roles Conceptualization, Writing – original draft
Affiliation Glucox Biotech AB, Stockholm, Sweden
- Nils Welsh
-
Roles Conceptualization, Writing – original draft
¶‡ These authors shared contribution as last author on this work.
Affiliation Science for Life Laboratory, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
- Per-Ola Carlsson
-
Roles Conceptualization, Writing – original draft
¶‡ These authors shared contribution as last author on this work.
Affiliation Science for Life Laboratory, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
Competing Interests
XW, AE, NW, and P-OC have no conflict of interest to disclose. PW and EW have applied for the following patents: Wilcke M, Walum E, Wikström P. Thiophene-based compounds exhibiting nox4 inhibitory activity and use thereof in therapy. 2013 Patent application number PCT/EP2013/055218, and the European patent application No. 18171556.6 submitted 2018-05-09 protecting the Nox4 selective compound GLX7013114. The funder Glucox Biotech AB provided support in the form of salaries for authors EW and PW. Glucox Biotech AB has supported this study by generating, characterizing and providing NOX inhibitors. This does not alter our adherence to PLOS ONE policies on sharing data and materials. NOX inhibitors will be shared pending patent publication.